(IN BRIEF) Basilea Pharmaceutica Ltd has received an additional USD 5.4 million from BARDA to continue development of its novel oral antibiotic ceftibuten-ledaborbactam etzadroxil. The antibiotic is being developed for complicated urinary tract infections, including pyelonephritis, particularly infections caused by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Investment, Pharma & Biotech, Science, Switzerland, Technology
Tagged Additional BARDA Support Brings Basilea Funding for Ceftibuten-Ledaborbactam to USD 30.8 Million, Administration for Strategic Preparedness and Response, Allschwil, anti-infectives, antimicrobial resistance, ASPR, BARDA, BARDA Awards Further Funding to Basilea for Ceftibuten-Ledaborbactam Development, Basilea, Basilea Advances Oral Antibiotic Candidate for Complicated Urinary Tract Infections, Basilea Pharmaceutica, Basilea Pharmaceutica Ltd, beta lactam beta lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI, boronic acid beta-lactamase inhibitor, BSLN, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, Cresemba®, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, fungal infections, Gram-negative bacteria, investigational drug, KPC, ledaborbactam, ledaborbactam etzadroxil, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, oral cephalosporin, OXA-48, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, Severe Bacterial Infections, SIX Swiss Exchange, Switzerland, U.S Department of Health and Human Services, U.S. FDA, USD 172 million contract potential, USD 30.8 million total funding, USD 5.4 million funding, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has received an additional USD 30 million from BARDA to support the ongoing phase 3 development of fosmanogepix, its novel first-in-class broad-spectrum antifungal candidate. The funding was awarded after Basilea met a prespecified enrolment milestone and … Read the full press release
Posted in Business, Financial, Government, Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Administration for Strategic Preparedness and Response, agreement number 75A50124C00033, Allschwil, antifungal treatment, aspergillosis, Aspergillus, ASPR, azole-resistant strains, BAL2062, BARDA, Basilea Pharmaceutica, Basilea Pharmaceutica Ltd, Basilea Secures New BARDA Tranche After Phase 3 Enrolment Milestone, Basilea Strengthens Antifungal Pipeline Funding Under Existing BARDA Agreement, Biomedical Advanced Research and Development Authority, broad-spectrum antifungal, Candida glabrata, Candida auris, candidemia, candidiasis, David Veitch, FAST study, Fast Track Designation, FDA, first in class antifungal, FORWARD study, fosmanogepix, Fosmanogepix Development Advances With Additional USD 30 Million BARDA Support, Fusarium, HHS, immunocompromised patients, invasive aspergillosis, invasive candidiasis, invasive fungal infections, Mucorales, multidrug-resistant fungal infections, orphan drug designation, OTA, Other Transaction Agreement, Phase 3 development, QIDP, Qualified Infectious Disease Product, Scedosporium, Switzerland, U.S Department of Health and Human Services, U.S. Food and Drug Administration, United States, USD 268 million potential non-dilutive funding, USD 30 million funding, USD 93 million committed funding
(IN BRIEF) Basilea Pharmaceutica has received an additional USD 13.3 million from BARDA to continue development of ceftibuten-ledaborbactam etzadroxil, an investigational oral beta-lactam/beta-lactamase inhibitor antibiotic being developed for complicated urinary tract infections, including pyelonephritis. The latest tranche brings BARDA’s total … Read the full press release
Posted in Business, Economy, Financial, Government, Healthcare, Industrial, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology, Transportation & Logistics
Tagged Administration for Strategic Preparedness and Response, Allschwil, antibiotic resistance, antimicrobial resistance, ASPR, BARDA, BARDA Funding Supports Basilea’s Efforts to Address Unmet Need in Oral Treatment of Complicated Urinary Tract Infections, Basilea, Basilea Pharmaceutica Ltd, Basilea Receives Additional USD 13.3 Million BARDA Funding to Advance Novel Oral Antibiotic Development, Basilea Secures Additional Non-Dilutive Funding to Prepare Ceftibuten-Ledaborbactam for Phase 3 Development, Basilea Secures Additional USD 13.3 Million BARDA Funding to Advance Development of Novel Oral Antibiotic Ceftibuten-Ledaborbactam, beta-lactam, beta-lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI combination, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, Gram-negative bacteria, infectious diseases, KPC, ledaborbactam etzadroxil, MDR Enterobacterales, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, OXA-48, phase 3 programme, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, SIX: BSLN, Switzerland, U.S Department of Health and Human Services, U.S. FDA
(IN BRIEF) Basilea Pharmaceutica has initiated FORWARD‑IM, a global Phase 3 trial evaluating fosmanogepix in adults with invasive mold infections. Building on positive Phase 1 and Phase 2 results—and following the FAST‑IC Phase 3 candidemia trial—this open‑label study will randomize about 160 patients to … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Amplyx Pharmaceuticals, Aspergillus spp., BARDA, Basilea Pharmaceutica Ltd, broad‑spectrum antifungal, Candida auris, candidemia, Cresemba®, FAST‑IC, FDA Fast Track, FORWARD‑IM, fosmanogepix, Fusarium spp., HHS ASPR, invasive candidiasis, invasive mold infections, Lomentospora prolificans, Mucorales, orphan drug, Pfizer, phase 3 study, PSI CRO AG, QIDP, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has secured an extra USD 39 million from BARDA under its Other Transaction Agreement, bringing potential non-dilutive funding to USD 268 million over 12 years. This new tranche will finance the ongoing phase 3 trial of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Allschwil, antibacterial, antifungal, ASPR, BAL2062, BARDA, Basilea Pharmaceutica Ltd, Cresemba®, fosmanogepix, HHS, invasive candidiasis, invasive mold infections, multidrug-resistant Candida auris, orphan drug, Other Transaction Agreement, partnership, QIDP, Switzerland, Zevtera®
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antifungal Drug, Asahi Kasei Pharma, Basilea Pharmaceutica Ltd, CHF 1.2 million, commercialization, Cresemba®, David Veitch, fungal infections, global sales, invasive fungal infections, Isavuconazole, Japan, market data, Market Growth, pharmaceutical industry, sales milestone
Basel, Switzerland, 24-11-2014 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the U.S. Food and Drug Administration (FDA) announced a public meeting of the Anti-Infective Drugs Advisory Committee to discuss the New Drug Application (NDA) for the investigational … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?